What's happening
This bill establishes a new process for listing and providing information on generic drugs in New York, enhancing transparency and updating prescription substitution rules.
Why it matters
Creates a new, more rigorous state-maintained list of generic drugs. The bill requires the NY Health Commissioner to publish a list of generic drugs that are FDA-approved, specifically excluding any drugs flagged by the FDA for bioequivalence problems, ensuring only trusted generics are eligible for substitution.
Mandates public disclosure of safety and efficacy data. Drug manufacturers must provide the state with detailed studies and data (including bioequivalence, therapeutic equivalence, adverse events, and testing methods) submitted to the FDA. All this information must then be made freely available to the public, increasing transparency for patients, prescribers, and pharmacists.
Standardizes substitution practices and prescription forms. The bill clarifies and updates language about when pharmacists can substitute generics, and ensures that prescribers’ intent regarding brand versus generic drugs is consistently communicated and documented, potentially reducing confusion or errors at the pharmacy.
Limits liability for prescribers. By codifying that prescribers are not civilly liable just for authorizing generic substitution according to these rules, the bill may encourage greater use of generics, benefiting patients through increased access and potentially lower drug costs.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
New York State Department of Health
The bill would require the commissioner to publish a list of qualifying generic drugs and interchangeable biological products and make manufacturers’ supporting studies and data freely available online.
Generic drug manufacturers
They would have to provide the department with studies, summaries and analytical methods submitted to the FDA, including equivalence and adverse-event data.
Pharmacists
The bill would tie prescription substitution requirements to the new list, which would exclude products the FDA identifies as having actual or potential bioequivalence problems.
Patients using generic drugs
They would gain free online access to manufacturers’ supporting safety and equivalence information through the department’s website.
Headline styles
Publish Generic Drug List
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Publish Generic Drug List
In Assembly Committee · Ways And Means · Sponsor Amy Paulin
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
4181
2023-2024 Regular Sessions
IN SENATE
February 6, 2023
Introduced by Sen. LANZA -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law and the education law, in relation to generic drug products; and to repeal paragraph (o) of subdivision 1 of section 206 of the public health law relating thereto
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraph (o) of subdivision 1 of section 206 of the public health law is REPEALED.
§ 2. The public health law is amended by adding a new section 280-d to read as follows:
§ 280-d. Generic drug products. 1. The commissioner shall establish and publish a list of drug products, referred to in this section as "generic drug" products, each of which shall meet the following conditions:
(a) The drug product has been certified or approved by the commissioner of the Federal Food and Drug Administration as being safe and effective for its labeled indications for use, and a new-drug application or an abbreviated new-drug application approved pursuant to the Federal Food, Drug, and Cosmetic Act is held for such drug product; and
(b) The commissioner of the Federal Food and Drug Administration has evaluated such drug product as: (i) pharmaceutically and therapeutically equivalent and has listed such drug product on the list of approved drug products with the therapeutic equivalence evaluations, provided, however, that the list prepared by the commissioner shall not include any drug product which the commissioner of the Federal Food and Drug Administration has identified as having an actual or potential bioequivalence problem or (ii) as an interchangeable biological product and has listed such product on the list of approved drug products with interchangeability.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD02150-01-3
2. The manufacturer of a generic drug product shall make available to the department the studies and summaries, including bioequivalence data, therapeutic equivalence data, and incidence of adverse events, and associated analytical methods, including dissolution data and test methods provided to the Federal Food and Drug Administration as part of the application for such generic drug product. The department shall make such information freely and publicly available on its website.
§ 3. Paragraphs (a) and (e) of subdivision 6 of section 6810 of the education law, paragraph (a) as amended by chapter 590 of the laws of 2011 and paragraph (e) as amended by chapter 357 of the laws of 2017, are amended to read as follows:
(a) Every prescription written in this state by a person authorized to issue such prescription shall be on prescription forms containing one line for the prescriber's signature. The prescriber's signature shall validate the prescription. Every electronic prescription shall provide for the prescriber's electronic signature, which shall validate the electronic prescription. Imprinted conspicuously on every prescription written in this state in eight point upper case type immediately below the signature line shall be the words: "THIS PRESCRIPTION WILL BE FILLED GENERICALLY UNLESS PRESCRIBER WRITES 'd a w' IN THE BOX BELOW". Unless the prescriber writes d a w in such box in the prescriber's own handwriting or, in the case of electronic prescriptions, inserts an electronic direction to dispense the drug as written, the prescriber's signature or electronic signature shall designate approval of substitution by a pharmacist of a generic drug product pursuant to [paragraph (o) of subdivision one of] section [two hundred six] two hundred eighty-d of the public health law. No other letters or marks in such box shall prohibit substitution. No prescription forms used or intended to be used by a person authorized to issue a prescription shall have 'd a w' preprinted in such box. Such box shall be placed directly under the signature line and shall be three-quarters inch in length and one-half inch in height, or in comparable form for an electronic prescription as may be specified by regulation of the commissioner. Immediately below such box shall be imprinted in six point type the words "Dispense As Written". Notwithstanding any other provision of law, no state official, agency, board or other entity shall promulgate any regulation or guideline modifying those elements of the prescription form's contents specified in this subdivision. To the extent otherwise permitted by law, a prescriber may modify only those elements of the prescription form's contents not specified in this subdivision. Notwithstanding any other provision of this section or any other law, when a generic drug is not available and the brand name drug originally prescribed is available and the pharmacist agrees to dispense the brand name product for a price that will not exceed the price that would have been charged for the generic substitute had it been available, substitution of a generic drug product will not be required. If the generic drug product is not available and a medical emergency situation, which for purposes of this section is defined as any condition requiring alleviation of severe pain or which threatens to cause disability or take life if not promptly treated, exists, then the pharmacist may dispense the brand name product at his regular price. In such instances the pharmacist must record the date, hour and nature of the medical emergency on the back of the prescription and keep a copy of all such prescriptions.
(e) No prescriber shall be subjected to civil liability arising solely from authorizing, in accordance with this subdivision, the substitution by a pharmacist of a generic drug product pursuant to [paragraph (o) of subdivision one of] section two hundred [six] eighty-d of the public health law.
§ 4. Paragraph (b) of subdivision 1 of section 6816-a of the education law, as added by chapter 776 of the laws of 1977, is amended to read as follows:
(b) The substituted drug product is contained in the list of generic drug products established pursuant to [paragraph (o) of subdivision one of] section [two hundred six] two hundred eighty-d of the public health law; and
§ 5. This act shall take effect on the ninetieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law and the education law, in relation to generic drug products; and to repeal paragraph (o) of subdivision 1 of section 206 of the public health law relating thereto
Purpose or general idea of bill
To make relevant information related to generic drugs freely and public- ly available.
Summary of specific provisions
Section one repeals paragraph (o) of subdivision 1 of section 206 of the public health law (PHL).
Read the full memo (961 words)
Section two adds a new section 280-c, named "generic drug products," to the PHL. The provisions included in subdivision one are taken from para- graph (o) of subdivision one of section 205 of the PHL, which has been repealed. This new subdivision provides that the health commissioner shall establish a list of drug products, which must be certified or approved and evaluated as therapeutically and pharmaceutically equiv- alent by the Federal Food and Drug Administration. Subdivision two provides that the manufacturer of a generic drug product shall make available to the department of health the studies and summaries (includ- ing bioequivalence data, therapeutic equivalence data, and incidence of adverse events) and associated analytical methods (including dissolution data and test methods) provided to the FDA as part of the application for such generic drug product. The department shall make such informa- tion freely and publicly available on its website.
Section 3 and section 4 change the references to paragraph (o) of subdi- vision 1 of section 206 of the PHL in the Education Law.
Section 5 provides the effective date.
Justification
New York State Law (paragraph (o) of subdivision 1 of section 206 of the PHL) provides that the health commissioner shall establish and maintain a list of generic drug products, which must meet specified conditions. The bill repeals this paragraph and transfers its language to a new section (280-b) of the PHL, named "generic drug products." This way, the provisions related to generic drugs are easily accessible.
The bill also introduces a new provision (subdivision 2 of the new section 280-c) to make relevant information related to generic drug products freely and publicly available.
The Center for Drug Evaluation and Research defines a generic drug as a drug product that is comparable to a brand/reference listed drug product in dosage form, strength, route of administration, quality and perform- ance characteristics, and intended use. Generic drugs are approved by the FDA and represent an affordable option for users. To receive approval by the FDA, generic drug manufacturers have to submit specified documents and reports, proving that their drug is bioequivalent to the respective brand name drug. The information that producers and manufac- turers provide to the FDA is not publicly available. For most generic drugs, consumers can access such information only by going through a formal FOIL request. This process can be extremely difficult and time consuming.
Moreover, the availability of such information is extremely valuable. The FDA has to process thousands of drug applications and mostly relies on studies submitted by the drug producers or manufacturers when making bioequivalence assessments.
Even when FDA procedures are precisely followed, differences between generic and brand name drugs can occur. For example, in 2008, the FDA declared a particular generic version of a brand name antidepressant drug as safe and effective. However, shortly thereafter it was discov- ered that the generic drug's side effects were different than those of the brand name drug. In 2012, the FDA reevaluated and announced that the generic drug is not the bioequivalent to the brand name drug.
The reversal was based on a FDA bioequivalence study which found that the generic drug achieved only 75% of the maximum drug concentration attained by the brand name product (potentially explaining the return of depression in patients switched to the; generic product). The generic manufacturer's product released much of its drug earlier than the brand's product. The dissolution rate greatly affects how a drug is released in the human body. This ultimately impacts the drug effects. The new results obtained by the FDA closely matched the results of inde- pendent organizations that tested the two drugs for bioequivalence. If the information that this bill makes public was available immediately, the time for a correction to be made may have been less than four years.
The biopharmaceutic studies and summaries, dissolution data, and test methods provided to the FDA by generic drugs producers must be avail- able. This way, such information can be reviewed and analyzed by experts who can conduct independent evaluations of the drugs. The intent of the bill is to encourage transparency in order to protect consumers. Certainly, consumers should have the option to have their prescription filled with a generic product, particularly since generics often cost less than brand name drugs. However, consumers must be informed of the drawbacks, if any, of taking a generic drug instead of the brand name drug. Consumers have the right to know what the differences between brand and generic drugs are and decide, with their physicians and phar- macists, whether the generic product is appropriate for them.
Prior legislative history
2022: S.5158- Referred to Health/A.1923 - Referred to Ways & Means
2021: S.5158- Referred to Health/A.1923 - Reported to Ways & Means
2020: S.2391-Referred to Health/A.612-A Referred to Ways and Means
2019: S.2391-A-Print Number 2391A/A.612-A Reported Referred to Ways and Means
2018: S.5471-A 5.5471 - Referred to Health / A.236-A - Passed Assembly
2017: Referred to Health / A.236 - Passed Assembly 2016: S.5099-A- Referred to Health/A.145-A -Passed Assembly
2015: S.5099-A- Referred to Health/A.145-A -3rd Reading
2014: S.6739-A- Referred to Health/A.8057-A- Referred to Ways & Means
2013: A.8057-A- Referred to Health
Fiscal implications
None.
Effective date
This act shall take effect on the ninetieth day after it shall have
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.